Repare Therapeutics Inc. - Common Shares (RPTX)
2.1250
+0.4750 (28.79%)
NASDAQ · Last Trade: Nov 17th, 3:49 PM EST
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.
Via Chartmill · November 17, 2025
Repare Therapeutics agrees to be acquired by XenoTherapeutics, offering shareholders cash, CVRs, and future milestone potential as the deal targets an early 2026 closing.
Via Benzinga · November 17, 2025
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Via Chartmill · November 17, 2025
Via Benzinga · November 17, 2025
Repare Therapeutics Jumps After Hours On $267M Global Licensing Deal With Debiopharm; Retail Traders Rush Instocktwits.com
Via Stocktwits · July 16, 2025
Via Benzinga · November 17, 2025
Via Benzinga · July 16, 2025
Via Benzinga · July 16, 2025
Via Benzinga · July 15, 2025
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Via Chartmill · July 15, 2025
On April 11th, 2025, Cathie Wood's Ark Invest sold shares in UiPath, Prime Medicine, and Repare Therapeutics, with notable gains and losses.
Via Benzinga · April 11, 2025
Via Benzinga · April 4, 2025
On Thursday, April 3, 2025, Cathie Wood-led Ark Invest purchased Robinhood stock worth $1.39 million amid a broader market slump.
Via Benzinga · April 3, 2025
Cathie Wood-led Ark Invest made substantial trades, buying Robinhood and CoreWeave shares and selling Roblox, Genius Sports, Roku, and Spotify shares.
Via Benzinga · March 29, 2025
Cathie Wood-led Ark Invest made notable trades, buying IRDM, BEAM, PACB, ABSI and selling ILMN, RPTX, AMGN, VEEV.
Via Benzinga · March 22, 2025
Ark Invest's Cathie Wood-led funds made significant trades involving GitLab, Intellia, Prime Medicine, UiPath, Ibotta, Roblox, Repare Therapeutics, and CareDx.
Via Benzinga · March 15, 2025

Via Benzinga · March 7, 2025

Via Benzinga · December 13, 2024

Via Benzinga · December 13, 2024

Via Benzinga · December 13, 2024

Repare Therapeutics shares MYTHIC trial data, highlighting Lunre+Camo's tolerability and efficacy in gynecologic cancers with FDA guidance on next steps.
Via Benzinga · December 13, 2024

Via Benzinga · December 13, 2024

U.S. stock futures advanced on Friday in premarket after declining on Thursday. The futures of all four major indices were trading higher.
Via Benzinga · December 13, 2024
